Item 8.01 Other Events.

On October 15, 2020, Sage Therapeutics, Inc. (the "Company") issued a press release announcing interim, topline data from the Company's ongoing Phase 3 open-label SHORELINE study evaluating zuranolone (SAGE-217) in the treatment of patients with major depressive disorder. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          Press release issued by Sage Therapeutics, Inc. on October 15, 2020.


104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses